StockGist

DXCM

GARP
DexCom, Inc.
NASDAQ· Healthcare· Medical - Devices
$84.68
2%· 2026-09-14

我的判断

由你记录,AI 研究刷新不会修改。复查日期到期后会出现在首页待办(UTC)。

加载中…

历史股价

加载中…
数据截至 2026-09-14
Market Cap
$31.95B
Revenue TTM
$4.89B
Latest Q GM
63.4%
Next 1Y Rev
12.4%
Forward PE
EV/EBITDA
20.7
P/S
6.43
FCF TTM
$1.38B

筛选结果

pipeline · 2026-09-14
Keep高增长 · Cheap · GARP
GARP Pool: growth 10-30%, MC/GP <= 11

研究记录

L2 基本面 → L3 估值 · 均由人工按需生成与刷新

L2 基本面 memo

尚无基本面 memo
上次生成失败:API错误: Error code: 402 - {'error': {'message': 'Insufficient Balance', 'type': 'unknown_error', 'param': None, 'code': 'invalid_request_error'}}
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。

L3 估值 memo

需先完成 L2 基本面 memo
先生成 L2 基本面报告,再做估值。

批注

DXCM 的投资备忘 · 买入价格/数量等也记在这里

财务报表

Metric
2026-06-30
Q2 2026
2026-03-31
Q1 2026
2025-12-31
Q4 2025
2025-09-30
Q3 2025
2025-06-30
Q2 2025
2025-03-31
Q1 2025
2024-12-31
Q4 2024
2024-09-30
Q3 2024
Revenue$1.31B$1.19B$1.26B$1.21B$1.16B$1.04B$1.11B$994.2M
Gross Margin63.4%62.9%62.9%60.5%59.5%56.9%58.9%59.7%
Operating Margin24.3%21.4%25.6%20.1%18.4%12.9%17%15.3%
Net Income$249.1M$199.5M$267.3M$283.8M$179.8M$105.4M$151.7M$134.6M
Diluted EPS0.640.510.680.70.450.270.380.34
Operating Cash Flow$269.2M$525.6M$294M$659.9M$303M$183.8M$301.4M$199.5M

公司简介

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

展开全文
WebsiteCEO: Jacob Steven Leach员工 10,200IPO 2005-04-14TTM 毛利率 62.5% · 经营利润率 22.9% · 净利率 20.1%

研究材料